Allergan plc is an American, Irish-domiciled pharmaceutical company that manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.

Plaintiff's law firm issued a press release on December 21, 2018, announcing the filing of the lawsuit. According to the press release, the Complaint alleges that, during the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts. Specifically, the Complaint alleges that throughout the Class Period, Allergan concealed from investors the fact that the Company's CE Mark for its textured breast implants and tissue expanders was expiring in Europe.

On March 21, 2019, the Court issued an Order consolidating cases and appointing Lead Plaintiff and Counsel. All future docketing was ordered to be done in the lead case 18-CV-12089.

Lead Plaintiff filed a consolidated amended Complaint on April 19, 2019. Defendants filed a Motion to Dismiss the consolidated amended Complaint on May 24. On September 20, the Court issued an Order granting in part and denying in part the Motion to Dismiss.

Lead Plaintiff filed a Motion for Class Certification on January 31, 2020. On September 29, the Court denied Lead Plaintiff's Motion for Class Certification. On December 7, the Court issued an Order appointing a new Lead Plaintiff and Lead Counsel. Lead Plaintiff filed a Motion for Class Certification on January 21, 2021. On September 8, the Court granted Lead Plaintiff's Motion for Class Certification.

Defendants filed a Motion for Summary Judgment on June 13, 2022. On December 12, the Court granted summary judgment in Allergan's favor. Lead Plaintiff filed a notice appealing the Court's judgment on January 11, 2023. On April 8, 2024, the Court of Appeals affirmed the District Court's ruling.